Kineta Share Holder Equity 2014-2024 | KANT
Kineta share holder equity from 2014 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Kineta Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$3 |
| 2022 |
$5 |
| 2021 |
$-12 |
| 2020 |
$56 |
| 2019 |
$-2 |
| 2018 |
$114 |
| 2017 |
$69 |
| 2016 |
$81 |
| 2015 |
$4 |
| 2014 |
$-8 |
| 2013 |
$2 |
Kineta Quarterly Share Holder Equity
(Millions of US $) |
| 2024-06-30 |
$-8 |
| 2024-03-31 |
$-6 |
| 2023-12-31 |
$3 |
| 2023-09-30 |
$3 |
| 2023-06-30 |
$8 |
| 2023-03-31 |
$-0 |
| 2022-12-31 |
$5 |
| 2022-09-30 |
$5 |
| 2022-06-30 |
$8 |
| 2022-03-31 |
$12 |
| 2021-12-31 |
$-12 |
| 2021-09-30 |
$32 |
| 2021-06-30 |
$41 |
| 2021-03-31 |
$49 |
| 2020-12-31 |
$56 |
| 2020-09-30 |
$37 |
| 2020-06-30 |
$45 |
| 2020-03-31 |
$53 |
| 2019-12-31 |
$-2 |
| 2019-09-30 |
$70 |
| 2019-06-30 |
$82 |
| 2019-03-31 |
$101 |
| 2018-12-31 |
$114 |
| 2018-09-30 |
$39 |
| 2018-06-30 |
$56 |
| 2018-03-31 |
$60 |
| 2017-12-31 |
$69 |
| 2017-09-30 |
$38 |
| 2017-06-30 |
$51 |
| 2017-03-31 |
$67 |
| 2016-12-31 |
$81 |
| 2016-09-30 |
$90 |
| 2016-06-30 |
$31 |
| 2016-03-31 |
$40 |
| 2015-12-31 |
$4 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$-8 |
| 2013-12-31 |
$2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
